Search Results - Declan O'Rourke

  • Showing 1 - 7 results of 7
Refine Results
  1. 1

    Nebulized Pentamidine-Induced Acute Renal Allograft Dysfunction by Siddhesh Prabhavalkar, Agnes Masengu, Declan O'Rourke, Joanne Shields, Aisling Courtney

    Published in Case Reports in Transplantation (2013-01-01)
    Get full text
    Article


  2. 2

    Dizygotic twin pseudochimaerism initially diagnosed as mosaic Klinefelter syndrome on microarray: case report by Declan O’Rourke, Aisling Lyons, Sumaiya Al-Rashdi, Elizabeth Whitmore, AnnMarie Hegarty

    Get full text
    Article


  3. 3

    Compound heterozygosity with PRRT2: Pushing the phenotypic envelope in genetic epilepsies by Christelle Moufawad El Achkar, Beth Rosen Sheidley, Declan O'Rourke, Masanori Takeoka, Annapurna Poduri

    Published in Epilepsy and Behavior Case Reports (2019-01-01)
    Get full text
    Article


  4. 4

    Autonomic instability, arrhythmia and visual impairment in a new presentation of MTFMT‐related mitochondrial disease by Caoimhe Howard, Arundhati Dev‐Borman, John Stokes, Declan O'Rourke, Ciara Gillespie, Eilish Twomey, Ina Knerr, Ritma Boruah

    Published in JIMD Reports (2023-03-01)
    Get full text
    Article


  5. 5

    An early analysis of the cost-effectiveness of a diagnostic classifier for risk stratification of haematuria patients (DCRSHP) compared to flexible cystoscopy in the diagnosis of b... by Andrew J Sutton, John V Lamont, R Mark Evans, Kate Williamson, Declan O'Rourke, Brian Duggan, Gurdeep S Sagoo, Cherith N Reid, Mark W Ruddock

    Published in PLoS ONE (2018-01-01)
    Get full text
    Article


  6. 6

    Stratifying risk of disease in haematuria patients using machine learning techniques to improve diagnostics by Anna Drożdż, Brian Duggan, Mark W. Ruddock, Cherith N. Reid, Mary Jo Kurth, Joanne Watt, Allister Irvine, John Lamont, Peter Fitzgerald, Declan O’Rourke, David Curry, Mark Evans, Ruth Boyd, Jose Sousa, Jose Sousa

    Published in Frontiers in Oncology (2024-05-01)
    Get full text
    Article


  7. 7

    Vasoactivity of rucaparib, a PARP-1 inhibitor, is a complex process that involves myosin light chain kinase, P2 receptors, and PARP itself. by Cian M McCrudden, Martin G O'Rourke, Kim E Cherry, Hiu-Fung Yuen, Declan O'Rourke, Muhammad Babur, Brian A Telfer, Huw D Thomas, Patrick Keane, Thiagarajan Nambirajan, Chris Hagan, Joe M O'Sullivan, Chris Shaw, Kaye J Williams, Nicola J Curtin, David G Hirst, Tracy Robson

    Published in PLoS ONE (2015-01-01)
    Get full text
    Article


Search Tools: